USFDA-approved parenteral peptide formulations and excipients: Industrial perspective

Parenteral preparations are sterile and non-pyrogenic formulations designed for delivery into the human or animal body by injection, infusion, or implantation. Peptides are widely employed as therapeutic aids in the healthcare business, accounting for more than half of the pharmaceutical market, wit...

Full description

Saved in:
Bibliographic Details
Published in:Journal of drug delivery science and technology 2024-05, Vol.95, p.105589, Article 105589
Main Authors: Kumar, Samarth, Sanap, Sachin N., Vasoya, Milan, Handa, Mayank, Pandey, Prachi, Khopade, Ajay, Sawant, Krutika K.
Format: Article
Language:English
Subjects:
Excipients
FDA
Parenteral peptides
Peptide-excipient interaction
Peptides formulations
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Parenteral preparations are sterile and non-pyrogenic formulations designed for delivery into the human or animal body by injection, infusion, or implantation. Peptides are widely employed as therapeutic aids in the healthcare business, accounting for more than half of the pharmaceutical market, with over 100 peptides prescribed worldwide. Although FDA-approved parenteral peptide formulations have transformed significantly, they also pose significant hurdles. The most difficult task for formulation experts is to formulate the peptides into parentally deliverable dose forms while maintaining their stability, safety and efficacy. The stability of the peptide formulation is mostly influenced by the excipient used since it constitutes the majority of the formulation. The selection of acceptable excipients is critical, necessitating a thorough examination of compatibility, safety, and their impact on product stability. Furthermore, knowing peptide interactions with certain excipients and container-closure systems is critical for its safety and efficacy. This review focuses on the excipients utilized in clinically approved peptide formulations, critical challenges associated with the development of parenteral peptide formulations, safety issues, evidence on the possible interaction between peptide-excipient and packaging material, and future perspectives. Readers will be able to comprehend excipients utilized in parenteral peptide formulations and FDA-approved peptide products in great detail. [Display omitted]
ISSN:1773-2247
DOI:10.1016/j.jddst.2024.105589